Cara Therapeutics Announces Positive Topline Results Long

Cara Therapeutics, Inc.NASDAQ

Description

⋅ Jul 1, 2022 5:12 AM

CARA: Cara Therapeutics, Inc.
2022-06-30 07:00:00
Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Nostalgia Paresthetica

Beyond Technical Analysis

Comments

Barkworth

⋅ Jul 14, 2022 8:07 AM

Worth around $13 with that product. Some decent upside, but being biopharma, not really interesting, considering the risk.